Corrigendum: Case report: Long remission and survival following immunotherapy in a case of pulmonary pleomorphic carcinoma
2024

Correction on Immunotherapy Case Report

Sample size: 1 publication

Author Information

Author(s): Wang Tongshan, Chen Muyang, Wang Anpeng, Zhang Hao

Primary Institution: Nanjing Medical University

Conclusion

The correction clarifies that the patient was treated with camrelizumab instead of pembrolizumab, achieving significant therapeutic success.

Supporting Evidence

  • The patient was initially treated with camrelizumab, achieving partial tumor remission.
  • The patient continued treatment for a total of 27 cycles of camrelizumab.
  • The patient transitioned to a combination therapy and then back to camrelizumab due to side effects.

Takeaway

This study talks about a patient with a rare lung cancer who did well on a specific treatment, and they fixed a mistake in the report about the medicine used.

Participant Demographics

68-year-old male patient

Digital Object Identifier (DOI)

10.3389/fimmu.2024.1530843

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication